Patent applications and USPTO patent grants for Fang; Lijuan.The latest application filed is for "modified fc fragment, antibody comprising same, and application thereof".
Patent | Date |
---|---|
Modified Fc Fragment, Antibody Comprising Same, And Application Thereof App 20220098307 - Zhang; JING ;   et al. | 2022-03-31 |
Cd3 Antigen Binding Fragment And Application Thereof App 20220041721 - Zhang; Jing ;   et al. | 2022-02-10 |
Bispecific antibody-mediated cancer therapy with cytokine-induced killer cell Grant 10,556,964 - Zhou , et al. Feb | 2020-02-11 |
Bispecific Antibody-mediated Cancer Therapy With Cytokine-induced Killer Cell App 20180312606 - Zhou; Pengfei ;   et al. | 2018-11-01 |
Construction and application of bispecific antibody EpCAM.times.CD3 Grant 9,777,073 - Zhou , et al. October 3, 2 | 2017-10-03 |
Construction and application of bispecific antibody EpCAMxCD3 App 20160090426 - Zhou; Pengfei ;   et al. | 2016-03-31 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.